Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2017

Published: Oct, 2017 | Pages: 254 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2017, provides an overview of the Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline landscape.

Human papillomavirus (HPV) is the most common viral infection of the reproductive tract. Human papillomavirus (HPV) has been found to be associated with several types of cancer. Risk factors include smoking, weakened immune system, long-term oral contraceptive use and chronic inflammation. Human papillomavirus (HPV) associated cancer have no symptoms until it is quite advanced, very serious and hard to treat.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Human Papillomavirus (HPV) Associated Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Human Papillomavirus (HPV) Associated Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 16, 8, 39, 6 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 2, 11 and 3 molecules, respectively.

Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Human Papillomavirus (HPV) Associated Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Human Papillomavirus (HPV) Associated Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Human Papillomavirus (HPV) Associated Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Human Papillomavirus (HPV) Associated Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Human Papillomavirus (HPV) Associated Cancer (Oncology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Human Papillomavirus (HPV) Associated Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
Introduction 5
Human Papillomavirus (HPV) Associated Cancer - Overview 6
Human Papillomavirus (HPV) Associated Cancer - Therapeutics Development 7
Human Papillomavirus (HPV) Associated Cancer - Therapeutics Assessment 19
Human Papillomavirus (HPV) Associated Cancer - Companies Involved in Therapeutics Development 27
Human Papillomavirus (HPV) Associated Cancer - Drug Profiles 49
Human Papillomavirus (HPV) Associated Cancer - Dormant Projects 230
Human Papillomavirus (HPV) Associated Cancer - Discontinued Products 232
Human Papillomavirus (HPV) Associated Cancer - Product Development Milestones 233
Appendix 244

List of Tables

Number of Products under Development for Human Papillomavirus (HPV) Associated Cancer, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Abion Inc, H2 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Admedus Ltd, H2 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Advaxis Inc, H2 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Amgen Inc, H2 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Antigen Express Inc, H2 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Atara Biotherapeutics Inc, H2 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Bionor Pharma AS, H2 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by BioNTech AG, H2 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Cancer Research Technology Ltd, H2 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Denceptor Therapeutics Ltd, H2 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Etubics Corp, H2 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by EyeGene Inc, H2 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Formune SL, H2 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Genexine Inc, H2 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Hookipa Biotech AG, H2 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by iBio Inc, H2 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Immunovaccine Inc, H2 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Inovio Pharmaceuticals Inc, H2 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Iovance Biotherapeutics Inc, H2 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by ISA Pharmaceuticals BV, H2 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Johnson & Johnson, H2 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Juno Therapeutics Inc, H2 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Karyopharm Therapeutics Inc, H2 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Kite Pharma Inc, H2 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by MedImmune LLC, H2 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Merck KGaA, H2 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by NeoImmuneTech Inc, H2 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Onconova Therapeutics Inc, H2 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Oryx GmbH & Co KG, H2 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by PDS Biotechnology Corp, H2 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Peregrine Pharmaceuticals Inc, H2 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Profectus BioSciences Inc, H2 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Rottapharm Biotech Srl, H2 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Selecta Biosciences Inc, H2 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Shantha Biotechnics Pvt Ltd, H2 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Shuttle Pharmaceuticals LLC, H2 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Sirnaomics Inc, H2 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Theravectys SA, H2 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by THEVAX Genetics Vaccine USA Inc, H2 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Transgene SA, H2 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by UbiVac LLC, H2 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Vaccibody AS, H2 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Vault Pharma Inc, H2 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Virometix AG, H2 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by VLPbio, H2 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Vyriad Inc, H2 2017
Human Papillomavirus (HPV) Associated Cancer - Dormant Projects, H2 2017
Human Papillomavirus (HPV) Associated Cancer - Dormant Projects, H2 2017 (Contd..1), H2 2017
Human Papillomavirus (HPV) Associated Cancer - Discontinued Products, H2 2017